Cargando…
Prognostic value of prognostic nutritional index and its variations in advanced non‐small‐cell lung cancer patients treated with anlotinib monotherapy
BACKGROUND: Anlotinib is a third‐line or further therapy for advanced non‐small‐cell lung cancer (NSCLC). However, the lack of simple biomarkers to predict the curative effect of anlotinib creates significant unmet needs in exploring the markers. This study aimed to explore the relationship between...
Autores principales: | Chen, Tian, Liang, Gaofeng, Xiang, Zhenfei, He, Jinxian, Xu, Xiaoyu, Tang, Mengqiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993602/ https://www.ncbi.nlm.nih.gov/pubmed/35179795 http://dx.doi.org/10.1002/jcla.24300 |
Ejemplares similares
-
Inflammation‐based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy
por: Chen, Tian, et al.
Publicado: (2022) -
Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Tang, Mengqiu, et al.
Publicado: (2021) -
Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib
por: Liu, Jingjing, et al.
Publicado: (2020) -
Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib
por: Chen, Tian, et al.
Publicado: (2022) -
The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy
por: Pan, Yuting, et al.
Publicado: (2023)